CRISPR Therapeutics (CRSP) Tops Q2 EPS by 115c

CRISPR Therapeutics (NASDAQ: CRSP) reported Q2 EPS of ($0.98), $1.15 better than the analyst estimate of ($2.13). Revenue for the quarter came in at $70 thousand versus the consensus estimate of $1.8 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Morgan Stanley Resumes Global Payments (GPN) at Equalweight
• Playboy to buy back 16.6M shares from Fortress at $1.05 each